Rosetta Genomics Advances New Diagnostic Tests into Development
Posted on: Thursday, 19 June 2008, 12:01 CDT
Rosetta Genomics has announced the advancement of three new diagnostic tests into its development pipeline.
The new development programs include response prediction to ovarian cancer treatment, predicting risk of gastric cancer recurrence, and differentiation of small cell from non-small cell lung cancer. The company expects to develop and market the new tests through its own clinical laboratory improvement amendments CLIA-certified laboratory, for which the company recently signed a binding acquisition term sheet.
Leveraging unique microRNA biomarkers identified using Rosetta Genomics's proprietary microRNA extraction and quantification methods, the new programs are expected to be clinically available during 2009-2010.
Ronen Tamir, executive vice president of marketing and communication at Rosetta, said: "Our rich product pipeline, combined with the upcoming acquisition of a commercial CLIA-certified laboratory, will position us to participate in such a growth trend in the molecular diagnostics industry."
Source: Datamonitor
Related Articles
- Researchers Exploit Genetic 'Co-Dependence' To Kill Treatment-Resistant Tumor Cells
- Columbus Cancer Foundation Honors Legendary Explorer
- Rosetta Genomics Announces Three New Diagnostic Tests to Enter Development
- Cytochroma Appoints R. Richard Wieland II As CFO
- Researchers Pinpoint Origins of Tumors Using MicroRNAs
- Oncolytics Biotech Inc. Completes Patient Enrolment in U.K. Phase Ia/Ib Combination REOLYSIN(R)/Radiation Clinical Trial
- Scientists Discover How to Activate Genetic 'Switch' That Stops Cancer
- Rosetta Genomics Ltd. And U.S. Genomics Inc. Announce Collaboration Agreement To Develop a Non-Invasive MicroRNA-Based Early Detection Test For Lung Cancer
- Deputy Director of Cold Spring Harbor Laboratory Cancer Center Wins Research Prize
- Some Breast Cancer Drugs Show Serious Flaws
 |
 |
User Comments (0)
RSS Feeds